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Abstract 4 
Background: The non-nucleoside reverse transcriptase inhibitor efavirenz is one of 5 
the most prescribed antiretroviral therapeutics. Efavirenz containing therapy has 6 
become associated with the occurrence of central nervous system side effects, 7 
including sleep disturbances, depression and even psychosis.  8 
Results: The investigation of efavirenz distribution required the development of a 9 
versatile and sensitive method. In addition to plasma, quantification was required in 10 
brain tissue and phosphate buffered saline. The assay presented here presented here 11 
was linear from 1.9ng/mL to 500ng/mL. Accuracy and precision ranged between 12 
93.7% and 99.5%, 1.5% and 5.6%, respectively. 13 
Discussion: The method developed here represents a versatile, sensitive and easy to 14 
use assay. The assay has been applied to in vitro and in vivo samples demonstrating 15 
reliable efavirenz quantification in multiple matrices.  16 
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1.1 Introduction 23 
Drug penetration into the central nervous system is an important factor influencing 24 
therapy efficacy and side effects in numerous diseases areas. This is a particularly 25 
relevant for the treatment of HIV, where the CNS represents a sanctuary site for the 26 
viral replication as well as a potential site for toxicity [1-3]. Efavirenz is a key 27 
antiretroviral and displays many desirable pharmacokinetic properties such as a long 28 
half-life allowing once daily dosing and potency against HIV [4]. Despite these 29 
favourable properties efavirenz-containing therapy is associated with the 30 
development of central nervous system (CNS) toxicities. There is a paucity of 31 
information describing the distribution and characterisation of drugs in the CNS [3]. 32 
We have validated a rapid, versatile and sensitive liquid chromatography tandem 33 
mass spectrometer (LC-MS/MS) for the detection of efavirenz in different matrices 34 
to investigate efavirenz distribution in to the CNS. 35 
The assay presented here was developed and validated in accordance with Food and 36 
Drug Administration (FDA) guidelines, assessing fundamental parameters including 37 
accuracy, precision and sensitivity [5]. Criteria such as linearity, accuracy (the 38 
degree of variation from known value, assessed by controls [QCs]), precision (the 39 
degree of variation within repeated measurements), selectivity (ensuring detection of 40 
the analyte and not an endogenous compound within the sample matrix) and 41 
recovery (determining the percentage of recovery and more importantly the 42 
reproducibility of the extraction process) were all assessed. The FDA guidelines also 43 
recommend a stability study be carried out. However or the purposes of this study a 44 
stability was deemed unnecessary as efavirenz has been in use for over 15 years and 45 
has been the subject of multiple studies. The stability of efavirenz at a variety of 46 
temperatures and matrices has previously been demonstrated [6-8].  47 
3 
Efavirenz was first licensed for the treatment of HIV in 1998, since then multiple 48 
methods for detection in plasma have been developed for LC-MS/MS. Many of the 49 
methods developed have been utilised to assess association with efavirenz plasma 50 
concentrations and CNS toxicity or polymorphisms in key proteins influencing 51 
efavirenz disposition [9, 10]. Some recently published methods show linearity with 52 
lower limit of quantification ranging from 20ng/mL to 300pg/mL [11, 12]. 53 
Despite the sensitivity and specificity of analysis LC-MS/MS, matrix effect is a well 54 
documented source of major concern [13]. Matrix effect may impact on various 55 
stages of the analytical process, such as ionisation of the analyte (either suppression 56 
or enhancement of ionisation) and extraction efficiency [5, 13]. Given the influence 57 
of the matrix on the quantification of an analyte, a change in matrix may have 58 
detrimental effects on the reliability of the assay. The method presented here was 59 
developed for robust quantification of efavirenz in multiple matrices (plasma, brain 60 
tissue homogenate and phosphate buffered saline [PBS]). The majority of published 61 
methods describe quantification of efavirenz in a single matrix [6, 8]. The greatest 62 
advantage of the assay developed here is robust quantification of efavirenz in 63 
multiple matrices, with minimal impact of matrix effect. The versatility 64 
demonstrated here will allow assessment of efavirenz in in vitro and in vivo samples. 65 
To investigate CNS concentrations of efavirenz, multiple LC-MS/MS methods have 66 
been developed to analyse efavirenz concentrations in CSF (cerebrospinal fluid) [14-67 
16]. Although assessing CSF is a step towards understanding efavirenz 68 
concentrations in the CNS, CSF and brain tissue concentrations of drugs may vary 69 
widely and may not represent the disposition of efavirenz in the CNS [17, 18]. 70 
 71 
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1.2 Methods and Materials 72 
1.2.1 Materials 73 
Efavirenz powder (>98% pure) was purchased from LGM Pharma inc (Boca Raton, 74 
USA). Lopinavir powder (>98% pure) was purchased from LGC Pharma (London, 75 
UK). All other consumables were purchased from Sigma Aldrich (Dorset, UK). 76 
 77 
1.2.2 Tuning for Efavirenz and Internal Standard 78 
Detection of efavirenz and internal standard (IS) lopinavir was conducted using a 79 
TSQ endura LC-MS/MS (Thermo scientific). Lopinavir was selected as IS due to 80 
similar log P (efavirenz 3.89, lopinavir 3.9) and has been shown previously not to 81 
interfere with efavirenz detection [4, 7, 19]. Tuning was performed using direct 82 
infusion (20µl/min) of a 500ng/mL stock of efavirenz with 50% mobile phase A 83 
(100% H2O [LC-MS/MS grade] 5mM ammonium formate), 50% mobile phase B 84 
(100% acetonitrile [ACN] 5mM ammonium formate) at a flow rate of 300µl/min. 85 
Ionisation was achieved via heated electron spray ionization in negative mode. 86 
Although positive mode is more commonly used efavirenz is poorly detectable in 87 
positive mode [6, 8]. The following parameters were optimised to achieve the 88 
highest signal intensity for efavirenz: spray voltage, sheath gas and auxiliary gas. 89 
The IS was then directly injected (500ng/mL) to ensure detection using the optimised 90 
efavirenz settings. Following optimization for the parent mass of efavirenz (315) and 91 
IS (628), selected reaction monitoring (SRM) scan was utilised for detection of the 92 
break down products. 93 
 94 
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1.2.3 Chromatographic Separation 95 
The chromatographic separation was achieved using a multi step gradient with a 96 
Hypersil gold C-18 column (Thermo scientific) (Table 1). The assay was conducted 97 
over 8 minutes at a flow rate of 300µl/min.  98 
 99 
1.2.4 Extraction from Plasma and PBS 100 
100 μl of sample (PBS was spiked with 20µl of ACN to aid efavirenz dissolution) 101 
was transferred to glass vials were 20µl of IS (2500ng/mL) were added to all 102 
standards, QC’s and samples. Samples were diluted with ACN (sample: ACN ratio 103 
1:4) and thoroughly vortexed. Samples were then centrifuged at 4000g for 10 104 
minutes at 4°C. The supernatant fraction was transferred to a fresh glass vial and 105 
evaporated, samples were placed in a rotary vacuum centrifuge at 30°C and then 106 
reconstituted in 140μl of H2O:ACN (60:40). 100µl of the sample was then 107 
transferred into 200µl chromatography vials. 5µl of each sample was injected for 108 
analysis.  109 
 110 
1.2.5 Extraction from Brain Tissue 111 
Rat brain tissue was homogenised in 3 volumes (W:V) of plasma. 100µl of brain 112 
tissue homogenate was then treated with ACN as detailed in the protein precipitation 113 
method detailed in the previous section. 114 
 115 
1.2.6 Assay Validation 116 
6 
The assay was validated according to the most recent FDA guidelines [5]. The 117 
following criteria were assessed: linearity, recovery, specificity, accuracy, precision, 118 
inter-assay and intra-assay variability. 119 
 120 
Linearity 121 
A calibration curve of efavirenz was prepared in rat plasma via serial dilution, 122 
ranging from 1.9ng/mL to 500ng/mL. Extraction was performed using protein 123 
precipitation. Linearity was assessed by 3 independent preparations of the standard 124 
curve. Maximum allowed deviation of standards was set at 15% of the stated value, 125 
excluding the lower limit of quantification where deviation was set at no more than 126 
20%. 127 
 128 
Recovery 129 
Recovery experiments were performed by comparing the results for extracted 130 
samples of efavirenz at three concentrations (20ng/mL, 100ng/mL and 400ng/mL) 131 
with non-extracted standards that were taken to represent 100% recovery.  132 
 133 
Selectivity 134 
The degree of interference from the matrix (due to potential interfering substances 135 
including endogenous matrix components, metabolites and decomposition products) 136 
was assessed via comparison of extracted blank samples with the lowest point of the 137 
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standard curve (lower limit of quantification). The lower limit of quantification was 138 
a minimum of 5 times greater than the background signal. 139 
 140 
Accuracy and Precision 141 
The accuracy of an analytical method describes the closeness of mean test results 142 
obtained by the method to the actual value (concentration) of the analyte. Accuracy 143 
was assessed by preparation of three concentrations (in the range of the standard 144 
curve 20ng/mL, 100ng/mL and 400ng/mL) with each preparation in triplicate. The 145 
mean value of each concentration should be within 15% of the stated concentration 146 
(except the lower concentration, where deviation should be less than 20%) [5]. 147 
Accuracy was calculated using the following formula: 148 
% 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =
𝑒𝑟𝑟𝑜𝑟
𝑠𝑡𝑎𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
 𝑥 100 149 
The precision of an analytical method describes the closeness of individual measures 150 
of an analyte when the procedure is applied repeatedly to multiple aliquots of a 151 
single volume of biological matrix. Precision of the assay was determined by 152 
preparation of three concentrations (in the range of the standard curve 20ng/mL, 153 
100ng/mL and 400ng/mL) with each preparation in triplicate. The mean value of 154 
each concentration should be within 15% of the stated concentration (except the 155 
lower concentration, where deviation should be less than 20%). Precision was 156 
calculated using the following formula: 157 
% 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑚𝑒𝑎𝑛 𝑎𝑠𝑠𝑎𝑦 𝑣𝑎𝑙𝑢𝑒
 𝑥 100 158 
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Accuracy and precision were assessed for intra and inter assay variability. The 159 
standard curve and QCs were prepared in triplicate and analysed 3 times. Variance in 160 
accuracy and precision should not vary within 15% of the stated concentration 161 
(except the lower concentration, where deviation should be less than 20%) within a 162 
single assay or between repetitions of the assay [5]. 163 
 164 
Animals and treatment 165 
Male Wistar rats (Charles River UK) weighing 180 – 220 g on arrival were used for 166 
PK analysis of efavirenz. Food and water were provided ad libitum. Treated and 167 
untreated Wistar rats were sacrificed using an appropriate schedule 1 method (rising 168 
concentration of CO2). Following termination brain was extracted and stored at -169 
80˚C. All animal work was conducted in accordance with the Animals (Scientific 170 
Procedures) Act 1986 (ASPA), implemented by the United Kingdom Home Office.  171 
 172 
1.2.7 Determination of Fraction Unbound of Efavirenz in Brain Homogenate 173 
Rat brain tissue (obtained from untreated wistar rats) was homogenised in 2 volumes 174 
(W:V) of 1% saline solution. Since efavirenz is highly protein bound, a dilution of 175 
brain tissue (10% and 20% brain tissue were prepared with 1% PBS) was used. 200 176 
μl of brain homogenate was spiked with 5000 ng mL-1 efavirenz and added to the 177 
donor chamber. The receiver chamber contained 350 μl of Sorensons buffer. The 178 
rapid equilibrium dialysis (RED) plate (Thermo, UK) was then placed in a shaking 179 
incubator for 4 hours at 37°C at 100 rpm. 250 μl were removed from the receiver 180 
chamber and frozen at -80°C for analysis. The fraction of drug unbound (fu) in brain 181 
tissue was then calculated from the diluted brain tissue using the following formula: 182 
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𝑈𝑛𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑓𝑢 =
(
1
𝐷)
[
1
𝑓𝑢(𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡)
− 1] + (
1
𝐷)
 183 
 184 
1.2.8 Efavirenz Penetration into Rat Brain Tissue 185 
Eight male Wistar rats (Charles River, UK) weighing 180-220g were dosed with 186 
efavirenz (10 mg/kg, 2 mL/kg 0.5% methylcellulose in dH2O) based on individual 187 
weight taken prior to dosing. Dosing was administered once daily via oral gavage 188 
over 5 weeks. The animals were terminated 2 hours after the final dose and blood 189 
was collected via cardiac puncture. Blood samples were centrifuged at 2000g for 10 190 
minutes at 4°C to separate plasma. Plasma was immediately frozen at -80°C and 191 
stored for later analysis. Brain tissue was also collected and following washing in 192 
phosphate buffered saline for 30 seconds 3 times, immediately stored at -30°C for 193 
analysis. All animal work was conducted in accordance with the Animals (Scientific 194 
Procedures) Act 1986 (ASPA), implemented by the United Kingdom Home Office.  195 
1.2.9 Statistics 196 
Data were assessed for normality using the Shapiro Wilk test. Statistical analysis was 197 
performed by Mann-Whitney U test and significance was defined as P <0.05. All 198 
data are given as mean with standard deviation. 199 
 200 
1.3 Results 201 
1.3.1 Tuning Settings 202 
10 
The aim of optimising the tuning settings was firstly to maximise the detection of 203 
efavirenz and secondly to ensure detection of the IS. The optimised global settings 204 
were negative ion 2700 V, sheath gas 35, aux gas 15 and sweep gas 0.  205 
 206 
In addition to detecting the parent molecule, the detection of the product ions of each 207 
compound was also optimised. By searching for both the parent and product ions, 208 
sensitivity and specificity are increased. This is particularly advantageous when 209 
analytes are contained in complex matrices such as plasma [20]. Table 2 shows the 210 
product ions produced during the selected reaction monitoring scan for efavirenz and 211 
IS. 212 
 213 
1.3.2 Extraction Efficiency from Plasma, Brain Tissue and PBS 214 
The recovery was measured at of the three QC concentrations (Figure 1). The mean 215 
recovery (across all 3 QCs) from plasma, brain tissue and PBS were 93% (standard 216 
deviation 2.9), 99% (standard deviation 4.49), and 95% (standard deviation 3.31), 217 
respectively. When recovery from to plasma was compared to recovery from brain 218 
tissue, there was a small but statistically significant difference in recovery at the low 219 
(92% vs 101 %, P = 0.001) and high (97% vs 101%QCs P = 0.04). When recovery 220 
from to plasma was compared to recovery from PBS, there was a small but 221 
statistically significant difference in recovery at the low QC (92% vs 99%, P = 222 
0.007). Recovery at all other levels showed no statistically difference.  223 
 224 
1.3.3 Assay Validation 225 
11 
 226 
Linearity 227 
Standards extracted from plasma showed good linearity (R2 = 0.9992). The peak area 228 
ratio (analyte to IS; variation of IS was less than 15% in each run) was proportional 229 
to the stated concentrations over the range of 500ng/mL to 1.9ng/mL. Figure 2 230 
shows a representative calibration curve. Calibration curve was generated using a 231 
quadratic equation with a weighting of 1/X. Although a linear equation produced 232 
an acceptable R2 (>0.99) the quadratic equation better described the 233 
relationship between signal response and standard concentration (R2 234 
>0.999). Both equations resulted in the assay passing (QC variability <15% 235 
at all levels). 236 
 237 
Selectivity 238 
The matrix effect of plasma was examined by comparing extracted blank plasma to 239 
extracted plasma spiked with 1.9ng/mL of efavirenz. Figure 3a shows the 240 
chromatogram produced by the extracted blank. There is a visible peak (area of 134) 241 
at the retention time of efavirenz (3.7 minutes). FDA guidelines require the lower 242 
limit of quantification produce a peak area of at least five fold greater than that 243 
observed in the blank matrix. Figure 3b shows the peak produced from the lower 244 
limit of quantification (1.9ng/mL). The peak area is 1491, which complies with FDA 245 
guidelines. Figure 3c shows the peak produced by the highest standard (500ng/mL). 246 
The bottom panels of figure 3 demonstrate the signal from the IS (retention time of 247 
3.59 minutes) in extracted blank plasma (3a), the lower limit of quantification of 248 
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efavirenz (3b) and highest standard of efavirenz (3c). The signal produced by IS 249 
shows no interference with efavirenz. 250 
 251 
Accuracy and Precision 252 
The accuracy and precision for each individual run at 3 QC levels (low (20ng/mL), 253 
medium (100ng/mL) and high (400ng/mL) is shown in table 3. The percentage error 254 
of accuracy fell below 15% for each of the 3 repeats (1 varied between -0.25% and -255 
11.45%, 2 varied between 0.01% and -6.32%, 3 varied between 0.78% and -4.66%). 256 
The percentage error of precision also fell below 15% for each of the 3 repeats (1 257 
varied between -5.52% and 11.05%, 2 varied between 2.93% and 5.66%, 3 varied 258 
between 1.25% and 3.78%). The QC concentrations were selected based on the 259 
anticipated concentrations in the study samples. FDA guidelines recommend QC the 260 
low QC be within 3 fold of the lower limit of quantification, the medium QC near 261 
the center of the linear range and a high QC near the upper limit of quantification. 262 
Supplementary figure 1 shows accuracy and precision for each individual run with 3 263 
QC levels conforming to FDA guidelines (low (5ng/mL), medium (200ng/mL) and 264 
high (400ng/mL). The percentage error of accuracy and precision fell below 15% for 265 
each of the 3 repeats. 266 
 267 
Inter-assay Variability 268 
The variability between assays was calculated to demonstrate that the assay 269 
maintained accuracy and precision across repetitions of the assay. Table 4 shows the 270 
variance of accuracy and precision calculated from the mean values of the 3 271 
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repetitions of the assay. The percentage error in accuracy fell below 15% across all 3 272 
repeats (range between -0.52% and -6.34). Percentage variance of precision also fell 273 
below 15% across all 3 repeats (range between 1.48% and 5.61%). Supplementary 274 
figure 2 shows the variance of accuracy and precision calculated from the mean 275 
values of the 3 repetitions of the assay (for low QC 5ng/mL, medium QC 200 ng/mL 276 
and high QC 400 ng/mL). Percentage variance of accuracy and precision fell below 277 
15% between all 3 repeats. 278 
 279 
1.3.4 Partial Validation of Brain Tissue Homogenate and PBS 280 
In order to assess the effect of changing matrix, QC’s were prepared and extracted 281 
from brain tissue homogenate and PBS. The extracted samples were then quantified 282 
using a plasma standard curve. The accuracy and precision for each matrix was 283 
assessed at 3 QC levels (low (20ng/mL), medium (100ng/mL) and high (400ng/mL) 284 
is shown in table 5. The percentage error of accuracy fell below 15% for each matrix 285 
demonstrating reliable quantification. 286 
 287 
1.3.5 Determination of Fraction Unbound of Efavirenz in Brain Homogenate 288 
The data generated from the rapid equilibrium dialysis experiments demonstrated a 289 
high degree of protein binding in brain tissue. The mean (± standard deviation) 290 
concentration of free efavirenz detected in was 209.7 ± 33.4 ng/mL, and 165 ± 22.0 291 
ng/mL, in 10% and 20% brain homogenate respectively. The protein binding in brain 292 
tissue homogenate was determined as 99.8% (10% homogenate) and 99.8% (20% 293 
homogenate). The average protein binding was 99.8%. 294 
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1.3.6 Efavirenz Penetration Into Brain Tissue 295 
The median plasma and brain tissue concentrations of efavirenz are shown in figure 296 
4. The median plasma concentration of efavirenz was 69.7 ng/mL (interquartile 297 
range [IQR] 44.9-130.6). The median concentration of efavirenz in brain tissue was 298 
approximately 10 fold higher, 702.9 ng/g (IQR 475.5-1018.0).  299 
 300 
1.4 Discussion 301 
The assay presented here represents a simple, robust and sensitive LC-MS/MS assay. 302 
In addition to accurate and precise quantification in plasma this assay has been 303 
shown to be versatile allowing quantification in brain tissue homogenate and PBS. 304 
The assay was fully validated in plasma. As the change in matrix represents a minor 305 
change to the assay only partial validation for the change of matrices was required, 306 
in accordance with guidelines [5].  307 
Primary validation was conducted in plasma satisfying FDA bioanalytical method 308 
development guidelines, demonstrating good accuracy, precision and linearity. 309 
Although full validation for different matrices is not required, matrix effects must be 310 
assessed for each matrix. The change in matrix may potentially affect the behaviour 311 
of the assay significantly. Brain tissue homogenate and cell culture media both 312 
contain different quantities of protein compared to plasma. As efavirenz is highly 313 
protein bound (99% in plasma) and poorly water soluble (<10µg/mL), the change in 314 
matrix has the potential to alter efavirenz recovery [21, 22]. As the change in matrix 315 
is considered a minor change, partial validation was acceptable. Partial validation 316 
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required the determination of intra assay variability in accuracy and precision [23]. 317 
These data demonstrate the versatility and reliability of the assay presented here. 318 
The sensitivity of the assay developed here is of a comparable standard to recent 319 
publications. Some of the newer assays surpass the sensitivity here, 200pg/mL in 320 
brain tissue and 300ng/mL in plasma [11, 24]. The greatest advantage of the assay 321 
developed here is the ability to assess efavirenz in plasma, brain tissue and PBS. The 322 
versatility of this assay demonstrates its suitability for application in the analysis of 323 
in vitro and in vivo samples. The assay may be further adapted to analyse efavirenz 324 
in additional matrices. It should also be noted that the assay was developed to assess 325 
a range of concentrations not predicted to be lower than 10ng/mL. As the lower limit 326 
of quantification (defined as >5x background) gave suitable sensitivity for the 327 
anticipated concentrations in the study samples the limit of detection was not 328 
established. The true limit of the assay is potentially much lower than the range 329 
validated here. 330 
The versatility of this assay has allowed for the quantification of efavirenz in 331 
multiple matrices. The data generated show the protein binding of efavirenz to be 332 
higher in brain tissue (99.8%) than either CSF (76%) or even plasma (99%) [25, 26]. 333 
The data generated in vivo shows efavirenz concentrations in brain tissue were 334 
approximately 10 fold higher than those in plasma. These data indicate CSF 335 
concentrations of efavirenz may underestimate exposure in the brain and warrant 336 
further investigation. 337 
One significant improvement would be to include the major metabolites of efavirenz, 338 
8OH efavirenz and 7OH efavirenz. Recent publications have demonstrated, in vitro, 339 
a higher cytotoxicity of 8OH efavirenz compared to the parent compound [27, 28]. 340 
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LC-MS/MS methods have been developed to examine efavirenz and its metabolites 341 
in CSF [29]. The authors investigated dose reduction of efavirenz (600mg once daily 342 
to 400mg once daily) and demonstrated 8OH efavirenz concentrations in CSF did 343 
not appear to be dependant on plasma concentrations of efavirenz.  344 
 345 
1.5 Conclusion 346 
This assay detailed here describes the optimisation of a robust, simple and sensitive 347 
LC-MS/MS assay. The final assay conformed to FDA bioanalytical development 348 
guidelines and was capable of assessing efavirenz in multiple matrices. The 349 
application of this assay has been applied to investigate efavirenz distribution in the 350 
CNS. 351 
 352 
1.6 Future Perspective 353 
The assay presented here has been developed and validated for the detection of 354 
efavirenz in rat plasma, rat brain tissue homogenate and PBS. However, future 355 
studies may be able to build upon the work presented here. Although our study 356 
focused on samples taken from rats, there is the potential to further utilise the assay 357 
to analyse samples from other species, such as mice and humans. Other matrices of 358 
interest may also be investigated, in particular CSF in (rat and or human). To adapt 359 
this assay would require partial validation, to investigate the potential effects of a 360 
change in matrix. Recent publications have implicated the metabolites of efavirenz in 361 
the development of CNS toxicity. The assay presented here could be further 362 
17 
modified to quantify not only efavirenz but also its major metabolites. This would 363 
allow future investigations to fully explore efavirenz penetration into the CNS. 364 
 365 
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Figures and Tables 480 
 481 
Figure 1 482 
Efavirenz recovery. 483 
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Figure 1 shows the percentage recovery for the low (a), medium (b) and high (c) 484 
QCs in extracted plasma, extracted brain tissue and PBS. Data is show percentage of 485 
unextracted standards. Statistically significant differences are highlighted using * (*P 486 
= <0.05), **P = <0.005) 487 
 488 
 489 
 490 
 491 
 492 
 493 
 494 
Figure 2 495 
Efavirenz Linearity 496 
Figure 2 shows the standard curve generated from extracted plasma standards of 497 
efavirenz over the range of 500ng/mL to 1.9ng/mL. 498 
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 504 
Figure 3 505 
Selectivity 506 
Figure 3 shows a representative chromatogram from blank plasma (A), lower limit of 507 
quantification (1.9ng/mL) (B) and the highest standard (500ng/mL) (C). The upper 508 
panel of each figure shows the peak produced by efavirenz (retention time 3.7). The 509 
lower panel show the peak produced by the IS (lopinavir) (retention time 3.58). 510 
 511 
 512 
 513 
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 514 
Figure 4 515 
Distribution of efavirenz in brain tissue and plasma  516 
Figure 4 shows the concentration of efavirenz in plasma and brain tissue determined 517 
following oral administration of efavirenz (10mg/kg) to male wistar rats over 5 518 
weeks. Data points represent median (plus IQR). 519 
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Chromatographic Conditions 528 
 529 
Time (mins) Mobile Phase A (%) Mobile Phase B (%) 
0.0 90 10 
0.1 90 10 
0.5 14 86 
5.0 8 92 
5.1 3 97 
6.0 3 97 
6.0 90 10 
8.0 90  10 
 530 
Table 1 shows the chromatographic gradient of mobile phase A (100% H2O, 5mM 531 
ammonium formate) and mobile phase B (100% ACN, 5mM ammonium formate) over 8 532 
minutes for the detection of efavirenz and IS. 533 
 534 
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24 
Product Ions Produced by SRM 541 
 542 
Compound Precursor  (m/z) Product (m/z) Collision Energy (V) 
  242.1 16.5 
Efavirenz 315 244.0 17.0 
  250.0 17.0 
  121.2 33.5 
Lopinavir 627 178.1 26.5 
  198.1 22.5 
Table 2 shows the parent mass, product ion and the collision energy for efavirenz and IS. 543 
25 
Intraday Accuracy and Precision 544 
 545 
  Assay 1 Variance 
of accuracy 
(%) 
Variance of 
precision 
(%) 
 Assay 2 Variance 
of accuracy 
(%) 
Variance of 
precision 
(%) 
 Assay 3 Variance 
of accuracy 
(%) 
Variance of 
precision 
(%) 
Low  
(20ng/ml) 
 19.95 -0.25 11.05  19.58 -0.42 5.66  20.16 0.78 2.74 
Medium 
(100ng/ml) 
 89.38 -10.62 5.52  100.01 0.01 3.88  95.34 -4.66 3.78 
High  
(400ng/ml) 
 354.21 -11.45 6.63  374.70 -6.32 2.93  394.97 -1.26 1.25 
 546 
 547 
Table 3 shows the accuracy and precision of 3 repetitions of the assay. Accuracy and precision were assessed in triplicate at 3 levels (low (20ng/ml), medium (100ng/ml) and 548 
high (400ng/ml). 549 
 550 
 551 
26 
Interday Accuracy and Precision 552 
 553 
 Average 
(ng/mL) 
Standard 
Deviation 
Accuracy 
(%) 
Precision (%) 
Low  
(20ng/mL) 
19.90 0.29 -0.52 1.48 
Medium 
(100ng/mL) 
94.91 5.33 -5.09 5.61 
High  
(400ng/mL) 
374.63 20.38 -6.34 5.44 
 554 
Table 4 shows the accuracy and precision of 3 repetitions of the assay (inter-assay variability). 555 
Accuracy and precision were assessed in triplicate of 3 QCs (low [20ng/mL], medium 556 
[100ng/mL] and high [400ng/mL]). 557 
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27 
Accuracy and Precision for Partial Validation in Brain Tissue and PBS 566 
 567 
  Average 
(ng/mL) 
Standard 
Deviation 
Accuracy 
(%) 
Precision 
(%) 
Low  
(20ng/mL) 
Brain Tissue 
PBS 
22.9 
22.5 
0.4 
0.6 
14.8 
12.3 
1.6 
2.6 
Medium 
(100ng/mL) 
Brain Tissue 
PBS 
100 
98.8 
3.7 
0.7 
0.0 
-1.2 
3.7 
0.7 
High  
(400ng/mL) 
Brain Tissue 
PBS 
387.9 
363.4 
2.4 
2.0 
-3.0 
-9.2 
2.4 
2 
 568 
Table 5 shows the results of the partial validation for brain tissue homogenate and PBS. 569 
Accuracy and precision were assessed in triplicate of 3 QCs (low [20ng/mL], medium 570 
[100ng/mL] and high [400ng/mL]). 571 
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